Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000601148 | SCV000711527 | uncertain significance | not specified | 2016-06-02 | criteria provided, single submitter | clinical testing | The p.Ser180Arg variant in PAX3 has not been previously reported in individuals with hearing loss or Waardenburg syndrome, but has been identified in 8/10406 Af rican chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadin stitute.org; dbSNP rs200679164). Although this variant has been seen in the gene ral population, its frequency is not high enough to rule out a pathogenic role. Computational prediction tools and conservation analyses do not provide strong s upport for or against an impact to the protein. In summary, the clinical signifi cance of the p.Ser180Arg variant is uncertain. |
Fulgent Genetics, |
RCV000765615 | SCV000896939 | uncertain significance | Alveolar rhabdomyosarcoma; Waardenburg syndrome type 1; Craniofacial-deafness-hand syndrome; Waardenburg syndrome type 3 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003718260 | SCV004506925 | likely benign | not provided | 2024-11-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004024887 | SCV005000129 | uncertain significance | Inborn genetic diseases | 2022-01-03 | criteria provided, single submitter | clinical testing | The c.540C>G (p.S180R) alteration is located in exon 4 (coding exon 4) of the PAX3 gene. This alteration results from a C to G substitution at nucleotide position 540, causing the serine (S) at amino acid position 180 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |